Table 3.
Polymeric Nanocarriers Obtained and Characterized in vivo for Delivery of Different Drugs for Lifestyle Disease
| Nanocarriers | Transporting Agent | Route of Administration | Animal Model | Application | Targeting |
|---|---|---|---|---|---|
| PEGylated nanocarriers148 | Rivaroxaban | Orally or i.v. | Healthy or blood vessel inflammation-induced albino rats | Venous thromboembolism treatment | – |
|
Chitosan and gum arabic polymeric nanocarriers and polysorbate-80 nanocarriers149 |
Glycyrrhizin and thymoquinone | Orally | Streptozotocin and nicotinamide–induced diabetic Wistar albino rats | Diabetes mellitus treatment | – |
| Eudragit RSPO-Lutrol F 127 nanocarriers150 | Felodipine | Orally | Healthy Sprague- Dawley rats | Hypertension treatment | – |
|
PLGA nanocarriers151 |
Curcumin capped gold nanoparticles | s.c. | Enalapril-induced cardiac hypertrophy Wister rats | Cardiac hypertrophy reduction | – |
|
PCL-PEG nanocarriers152 |
Cilostazol | Orally | Healthy Wistar rats | Peripheral arterial disease treatment | – |
| Eudragit S 100 nanocarriers153 | Budesonide | Orally | Colitis-induced Wister albino rats | Inflammatory bowel disease treatment | pH-sensitive |
Abbreviations: i.v., intravenous; s.c., subcutaneous; PCL, poly-e-caprolactone; PEG, poly(ethylene glycol); PLGA, poly(lactide-co-glycolide).